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MY COMRADE implementation intervention
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Abstract
Background: For the majority of patients with multimorbidity, the prescription of multiple long-term medications
(polypharmacy) is indicated. However, polypharmacy poses a risk of adverse drug events, drug interactions and
excessive treatment burdens. To help general practitioners (GPs) conduct more comprehensive medication reviews
for patients with multimorbidity, we developed the theoretically-informed MultimorbiditY COllaborative Medication
Review And DEcision Making (MY COMRADE) implementation intervention. In this study, we assessed the feasibility
and acceptability of MY COMRADE by GPs.
Methods: A non-randomised feasibility study using a qualitative framework approach was conducted. General
practices were recruited by purposively sampling from interested GPs attending continuing professional
development meetings (CPD) in southwest Ireland. Participating practices were instructed on the MY COMRADE
implementation intervention which has five components: (i) action planning; (ii) allocation of protected time; (iii)
peer-supported medication review; (iv) use of a prescribing checklist and (v) self-incentives (allocation of CPD
points). GPs in participating practices agreed to conduct medication reviews on multimorbid patients from their
own caseload using the MY COMRADE approach. After completing these reviews, qualitative interviews were
conducted to evaluate GPs’ experiences of the intervention and were analysed using the framework method.
Results: GPs from ten practices participated in the study. The GPs reported that MY COMRADE was an acceptable
approach to implementing medication review in general practice, especially for complex patients with
multimorbidity. Action plans for the medication reviews varied between practices, but all reviews led to
recommendations for optimising medications and patient safety. Many GPs felt that using the MY COMRADE
approach would ultimately lead to more efficient use of their time, but a minority felt that the time and cost
implications of using two GPs to review medications would not be sustainable unless greater incentives were used.
Conclusions: This study demonstrates that MY COMRADE is an acceptable and feasible approach to supporting
comprehensive medication reviews for patients with multimorbidity. These findings indicate that a large scale trial
of the effectiveness of MY COMRADE is now required to fully evaluate its potential to change prescribing behaviour
and improve downstream outcomes such as prescribing appropriateness and treatment burden.
Trial registration: ISRCTN registry: ISRCTN34837446.
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Background
Internationally, healthcare policy makers strive to deliver
generalist management of chronic disease in a primary
care setting [1]. Over 50% of patients with chronic dis-
ease have multimorbidity (multiple chronic diseases) [2],
which can lead to challenges in the provision of clinical
care foremost of which is the management of multiple
medications [3]. Multimorbidity is associated with higher
rates of potentially inappropriate prescribing and adverse
drug effects [4]; therefore, it is recommended that
patients with multimorbidity have their medications
reviewed periodically [5]. However, uncertainty about
how to balance guideline adherence and minimising the
negative effects of polypharmacy can deter primary care
physicians or general practitioners (GPs) from actively
reviewing medications for their multimorbid patients
[6, 7]. As the prevalence of multimorbidity continues to
rise, interventions to support structured medication re-
view for patients with multimorbidity are a priority [8].
Existing approaches to enhancing medication review
in general practice incorporate pharmacists [9], geriatri-
cians [10] or clinical decision support systems [11]. Sys-
tematic reviews of the effects of these interventions
have shown inconsistent results with only limited evi-
dence to show that they reduce medication-related
problems or lead to meaningful clinical improvements
[9–11].
In response to these limitations, we developed a novel
implementation intervention to support medication re-
view by GPs for patients with multimorbidity. Imple-
mentation interventions are complex interventions that
aim to align clinical behaviour with evidence-based prac-
tice [12]. The Medical Research Council UK (MRC)
states that if such interventions are informed by empir-
ical data and theory, they are easier to evaluate, more
likely to be implemented and more likely to be worth
implementing [13].
We followed the guidance of the MRC by first con-
ducting a synthesis of the existing evidence about GPs’
perceptions of managing multimorbidity (see Fig. 1)
[14]. We added to this by conducting a qualitative
interview study with GPs on medication management
in multimorbidity [15]. We found that when the man-
agement of patients with multimorbidity gets compli-
cated, GPs often seek advice from each other [15].
These discussions between GPs take place on an
Fig. 1 Key steps in the development and feasibility testing of the MY COMRADE intervention, following stages of the UK Medical Research
Council guidance on the development and evaluation of complex interventions in healthcare [30]
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informal basis and are rarely documented in the med-
ical notes, yet they represent an important source of
peer support for decision-making in primary care. We
developed an implementation intervention that takes
advantage of these discussions by formalising them as
structured medication reviews for patients with multimor-
bidity. We applied theories of behaviour (the COM-B),
models of intervention design (the Behaviour Change
Wheel) and taxonomies of behaviour change techniques
to our empirical data to develop the Multimorbidity
COllaborative Medication Review And DEcision
Making (MY COMRADE) implementation intervention
[16]. In the MY COMRADE implementation interven-
tion, two GPs use protected time to conduct a struc-
tured medication review and generate an optimised
medication management plan for a complex multimor-
bid patient together.
Although using empirical evidence and theoretical
methods in the development of MY COMRADE in-
creases its likelihood of success, the MRC guidance
also stresses the importance of conducting feasibility
and pilot studies of new interventions in real-world
conditions prior to conducting larger and more costly
evaluations of effectiveness. Feasibility and pilot stud-
ies can address key uncertainties, inform refinements
and identify problems that might occur in an ensuing
definitive trial of a complex intervention or can deter-
mine whether a full-scale study of an intervention is
warranted [17]. In a framework of pilot and feasibility
studies proposed by Eldridge et al. [17], a feasibility
study for a future definitive randomised controlled trial
asks whether the future trial can be done, should be
done and, if so, how (see top box in Fig. 1). Pilot stud-
ies are a subset of feasibility studies: they ask the same
questions about feasibility but have a particular design
feature: in a pilot study (that might or might not be
randomised), the future definitive trial, or part of it, is
conducted on a smaller scale.
Therefore, prior to conducting a larger trial of MY
COMRADE, we conducted this study to examine the
feasibility of the MY COMRADE approach to imple-
menting structured medication review for patients with
multimorbidity. We assessed feasibility by examining
three key uncertainties: is MY COMRADE acceptable to
GPs; is it adaptable by GPs working in different contexts
and do recommendations for medication optimisation
arise from the medication reviews.
Methods
Study design
A non-randomised feasibility study of the MY COM-
RADE implementation intervention was conducted,
using a qualitative framework approach.
Setting and participants
The study was conducted between December 2014 and
July 2015. General practices were recruited by purpos-
ively sampling from interested GPs attending continuing
professional development meetings (CPD) in southwest
Ireland. A brief description of the study was provided by
one researcher (CS), and GPs who were interested
signed a clipboard. From this list, practices were purpos-
ively sampled by location (urban/rural), practice size (≤3
GPs/>3 GPs) and GP training practice (yes/no). The only
inclusion criterion was that practices have at least two
qualified GPs. It was agreed a priori that ten practices
manifesting this range of criteria would be sufficient to
demonstrate feasibility [16]. The researcher (CS) visited
each practice to describe the implementation intervention
to GPs and to advise them on how they should proceed
with using it. Written information and instruction leaflets
were also provided (Additional files 1 and 2).
The intervention
The development and specification of the implementa-
tion intervention are described in detail elsewhere [16].
In summary, MY COMRADE includes five behaviour
change techniques (labelled below in italics). The princi-
pal behaviour change technique is peer support: two
GPs conduct a structured medication review together to
generate an optimised medication management plan for
a complex multimorbid patient. The medication review
is guided by a prescribing checklist (prompts and cues),
which is provided to GPs in paper form and was adapted
from the published “NO TEARS” medication review tool
(Additional file 3) [18]. The other three behaviour
change techniques are: (i) developing a practice action
plan for conducting the reviews (action planning); (ii) al-
locating protected time within the GPs’ schedule to con-
duct the reviews (restructuring of the social environment)
and (iii) recording the activity for the purposes of CPD
points for GPs (self-incentives).
Procedure
In each practice, GPs were asked to select complex mul-
timorbid patients who were either prescribed ten or
more medications or five or more medications with an-
other complicating factor (i.e. impaired cognition, psy-
chosocial complexity, poor life expectancy, etc.) from
their caseload. They agreed to conduct medication re-
views for at least six of these patients using the MY
COMRADE approach. They were advised that each
medication review would take approximately 10–15 min.
Evaluation and outcomes
We evaluated GPs’ experiences of the intervention in
semi-structured interviews after they had completed
their medication reviews. The topic guide for the
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interviews was informed by the implementation outcome
framework [19] [20] (topic guide provided in Additional
file 4). This framework includes eight implementation out-
comes (acceptability, adoption, appropriateness, feasibility,
fidelity, implementation cost, coverage and sustainability)
which we aligned with our research objectives. We also
asked GPs to describe how they conducted their collab-
orative reviews and any recommendations on medications
that arose in each review. We encouraged GPs to refer to
notes they had made during the medication reviews to
help them recount the details of each case.
Analysis
All evaluation interviews were audio-recorded, tran-
scribed verbatim and entered into NVivo software to fa-
cilitate data coding. Field notes and memos were also
analysed. We used the framework approach for data ana-
lysis [21]. After familiarisation and immersion in the
transcripts, sections of data were indexed into the eight
headings of the implementation outcome framework,
which were in turn mapped to the three specific research
objectives. We mapped data on acceptability and adoption
to the first research objective (i.e. if MY COMRADE was
acceptable to GPs) and used data on the implementation
cost and sustainability to develop a subtheme on longer
term acceptability. We mapped feasibility and fidelity to
the second research objective (i.e. adaptability by GPs
working in different contexts) and mapped appropriateness
and coverage to the third research objective (i.e. if recom-
mendations for medication optimisation arose from the
medication reviews). Inductive themes that did not fit with
the a priori framework were added to the matrix. Themes
and subthemes were compared across practices to map the
range of experiences, provide explanations and find associ-
ations. All interviews were indexed, charted and analysed
by CS, and three interviews were separately indexed and
analysed by CB and MB. In a consensus meeting, all three
researchers presented their analysis, discussed divergent
accounts and refined emerging themes. The study was ap-
proved by the Clinical Research Ethics Committee, Univer-
sity College Cork (ECM3(vvvvv)19/11/14). The Template
for Intervention Description and Replication (TIDIER)
checklist was used to guide the study report.
Results
From the GPs who expressed an interest in the study, 15
were contacted before ten practices agreed to participate
(10/15, 66%). Practice characteristics are shown in Table 1.
Is MY COMRADE acceptable to GPs?
In all interviews, GPs reported positive experiences of
the intervention. Many said it sounded acceptable at
first hearing:
I felt I had something to gain and my patients had
something to gain as well. I emailed you (back) very
quickly because I was positive about the whole thing.
gp4
Other GPs felt it would help them with patients they
were worried about:
the minute we heard about it, patients pop up in your
head-you know these ones who are on like 15 tablets
and they are really complicated. gp11
The focus of the intervention on prescribing was a key
factor:
The whole prescribing issue is a potential mine field…
anything that concentrates my brain or helps me be a
little bit more circumspect on what we are prescribing
is a good thing. gp2
The use of peer support was viewed as acceptable be-
cause it was compatible with the GPs’ usual behaviour in
practice:
There’s hardly a day goes by where I don’t say can I
talk to you about this or she says can I talk to you
about that gp9
Cost and sustainability
For GPs, the biggest perceived cost of MY COMRADE
was time. The duration of the reviews (5 to 30 min) var-
ied with the GPs’ knowledge of the patient, the number
of medications prescribed and the number of problems
exposed. Additional work was often generated by the re-
views such as referral to specialists; contacting local
pharmacists and multiple consultations with patients to
discuss potential changes. The majority of GPs did not
Table 1 Characteristics of the practices participating in the
feasibility study
% of practices (n)
Practice location
Rural 20 (2)
Urban 50 (5)
Mixed 30 (3)
Size of practice
≤3 GPs 40 (4)
>3 GPs 60 (6)
GP training practice
Yes 50 (5)
No 50 (5)
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feel negatively about this work, seeing it as part of their
job and potentially time saving in the end:
I wouldn’t really call it additional workload because if
it’s in the patient’s interest its part of my work. gp4
Regarding sustainability, many GPs said they intended
to continue using the intervention as it was practical,
useful and relevant and had potential benefits for patient
care. Others felt that external factors were needed to en-
sure it was sustained, such as financial remuneration or
punitive measures (i.e. external audit of medications).
How was the implementation intervention adapted
by GPs?
We determined how GPs implemented and adapted the
five behaviour change techniques incorporated into MY
COMRADE, by asking about the feasibility of and fidel-
ity to the intervention. The results are shown in Table 2.
All participating practices implemented the intervention
but as implementation took longer in some practices
than others, we began to set specific dates for follow-up
interviews. The imposed deadline may have led to fewer
collaborative reviews in some practices, but it revealed
the competing demands on GPs’ time as they tried to fit
the intervention into existing practice. The median num-
ber of MY COMRADE reviews per GP pair was 4 (inter-
quartile range 3–5.75).
1. Action planning
Action plans varied from agreeing to conduct the
reviews before or after consultation sessions, to
using time already allocated to non-consultation
activities (i.e. practice meetings) for reviews. Three
practices planned to use gaps in their schedules to
conduct reviews opportunistically—this approach
only worked if one of the GPs was championing
the intervention (Practices 3, 7, 10).
2. Restructuring of the social environment
GPs reported two benefits to conducting medication
reviews outside of consultations. First, they could
focus on the medications without being distracted
by the patients’ presenting crisis or catastrophe or
issue with the hospital or something gp14. Second,
GPs liked going into the consultation already
prepared for making suggestions, reporting that it
was easier to discuss it with someone else first gp11.
3. Social support
Articulating and justifying patients’ medications to
another GP appeared to be the most important
component of the implementation intervention.
GPs who experimented with conducting reviews
on their own (using only the checklist) reported that
the collaborative approach was better as it revealed
their prescribing “blind spots” and was often quicker
than doing it alone. GPs adapted the intervention
by conducting reviews with a pharmacist (Practice
1) or a specialist (Practice 9): this approach also led
to recommendations for medication change and
provided reassurance to GPs. Two GPs conducted
reviews with patients: they reported these reviews
took longer, were more confusing for the GP and
did not generate the same clear actionable
recommendations (Practice 5 and 7).
4. Prompts and cues
All but one practice used the prescribing checklist
in reviews. GPs reported that the checklist was
necessary for giving early reviews as structure, but
they referred to it less frequently as time went on.
The checklist continued to be useful in cases where
the GP had no pre-existing concerns about the
medications, by directing and prompting review of
the entire prescription.
5. Self-incentives
Although gaining CPD points was not a primary
motivating factor for participating GPs, they all
reported that they would record the reviews for
CPD purposes.
What recommendations for medication optimisation
arose from the reviews?
Every review led to recommendations for optimisation
of medications. In many cases, GPs were shocked at the
number of recommendations that arose:
Table 2 Implementation of the five behavioural change techniques in the MY COMRADE intervention by participating practices
Practice number
1 2 3 4 5 6 7 8 9 10
Action planning + + − + + + − + − −
Restructuring social environment + + + + + + + + − +
Social support + + + + + + + + + +
Prompts and cues (checklist) + + + + + + + + − +
Self-incentives (CPD points) − + + + − + − + − −
Number of medication reviews completed 4 4 3 6 6 3 8 3 1 5
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It was amazing, took us right out of our comfort zone.
I thought at the worst we would find one or two
things that we might change … But in each of the
cases, we were able to question about 50% of their
actual meds gp9
The most common recommendation involved de-
prescribing medications for which there was no clear
indication (Practices 1, 3–7, 10), new evidence for use
(Practices 4, 7, 8, 10) or a duplicate (Practices 1, 3, 4,
6–8). Recommendations for de-prescription most com-
monly involved bisphosphonates, high-dose proton
pump inhibitors, statins and aspirin for primary pre-
vention, long-term analgesics and benzodiazepines.
In some reviews, the recommendations included up-
dating tests and vaccinations (Practices 1, 2, 4, 5, 7, 8),
and ensuring patients were getting adequate follow-up
from specialist teams (Practice 2, 4, 7, 8). The reviews
led to updating patients’ records (Practices 1, 4–8, 10)
and highlighting patient specific risks (i.e. allergies)
(Practices 1, 4, 7). Indicated preventative medications
were added or adjusted in Practices 1, 2, 4, 7, 9.
Discussing recommendations with patients
This was an inductive subtheme within the theme of
recommendations arising from the reviews. GPs varied
in their approach to discussing the recommendations
with patients: some waited until the patient’s next con-
sultation while others called patients in to discuss their
recommendations. GPs said that patients reacted
favourably to hearing their case had been discussed at a
practice level. Most patients agreed to making the rec-
ommended changes but after discussion with the GP, a
minority (n = 2) opted not to.
Discussion
Prior to conducting a larger trial of MY COMRADE, we
needed to demonstrate the feasibility of the intervention
by addressing key uncertainties. Our key uncertainties
relate to our three research objectives (is MY COM-
RADE acceptable to GPs; is it adaptable by GPs working
in different contexts and do recommendations for medi-
cation optimisation arise from the medication reviews).
By addressing these questions using a systematic ap-
proach and empirical evidence, the feasibility of the
intervention has been confirmed.
Our findings show that an implementation interven-
tion using protected time and peer support supported
the conduct of comprehensive structured medication re-
views. The intervention was acceptable to GPs; was
readily adaptable by GPs working in different contexts
and led to optimised medication management plans for
all of the complex multimorbid patients that were
reviewed. These findings are encouraging and indicate
that proceeding to a larger scale trial evaluation of MY
COMRADE is worthwhile. The study has also provided
important information in preparation for the future trial.
For example, we were interested in how GPs adapted the
five behaviour change techniques in MY COMRADE to
the context of their own practices [22]. Peer support ap-
peared to be the key technique in generating recommen-
dations for medication optimisation, but GPs innovated
in where they found this support. While other profes-
sional sources (i.e. pharmacist, specialist) were reported
to be useful, conducting the review with patients only
was not: therefore, professional social support will be a
compulsory component of any future iterations of the
intervention. Insufficient time appeared to be the only
reason participants did not do all six reviews, and many
GPs felt that incentives are needed to support and sus-
tain allocation of their time to this activity. This may not
be intervention specific: when a system is over con-
strained with competing demands, as is the case in Irish
general practice, the resources needed to make any new
intervention succeed may be unavailable [23]. However,
more substantial incentives may lever behaviour change
and warrant consideration prior to embarking on a large
scale evaluation of MY COMRADE.
The aim of MY COMRADE is to implement an
evidence-based practice: medication review for patients
with multimorbidity. Ultimately, we would like to show
that MY COMRADE positively impacts on outcomes
such as prescribing appropriateness and cost savings due
to reductions in unnecessary medications. However,
these outcomes are further down the causal pathway
and are influenced by a host of other factors. We have
not focused on outcomes down the causal pathway in
this study to avoid underestimating the value of the im-
plementation intervention to positively change behaviour
in line with best practice [24].
Comparison with other work
Many interventions to support medication review in
primary care have used pharmacists (10–12). These in-
terventions have shown inconsistent results and evi-
dence of their impact on clinical outcomes is lacking.
Furthermore, such approaches are not a pragmatic op-
tion in Irish healthcare where few publically funded
community pharmacists exist [25]. Our study showed
that the MY COMRADE implementation intervention
enabled GPs to identify and rectify suboptimal pre-
scribing without requiring input from external
personnel (i.e. a pharmacist) other than robust, reli-
able and credible internet sources of prescribing infor-
mation (i.e. the British National Formulary).
Alternative approaches to medication review utilise com-
puter decision support or integration of multiple guide-
lines. These approaches do not incorporate professional
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judgement or provide the peer support that difficult clinical
decisions often require in patients with multimorbidity
[26]. In contrast, peer-supported reviews permit profes-
sional judgement, individualised care and can help main-
tain professional standards [27].
In MY COMRADE, two GPs undertake a structured
medication review, and together, they generate an opti-
mised medication management plan for a complex mul-
timorbid patient. Evidence of the value of collaborative
decision-making between GPs to improve patient care,
such as quality circles or practice-based small group
learning programmes, has emerged in recent years and
supports the intra-disciplinary nature of our intervention
[27]. Quality circles and related groups provide an op-
portunity for reflective practice and discussion of troub-
ling or challenging patient cases between GPs. Evidence
shows that these groups can reduce medication costs,
improve the prescribing of generic medications [27–29],
and provide social support and protection against GP
burnout [30]. In an exploration of cases brought by GPs
to such a programme, many related to complexities in
the management of patients with multimorbidity [30].
Strengths and limitations
We developed this implementation intervention in line
with the guidance issued by the MRC. Although the
MRC advocates the use of the theory in the development
of complex interventions [13], some researchers have
questioned the usefulness of theory in this process [31,
32]. In our experience, applying theory to bottom-up
data has led to an intervention which fits appropriately
with existing practice and has shown real potential to
change GPs’ prescribing behaviour.
To address pre-existing uncertainties associated with
MY COMRADE, we used the framework method to-
gether with the implementation outcome framework [19,
20]. Framework analysis was specifically designed for
data analysis in health services research, making it an
appropriate choice for this work [21].
For practical reasons, we relied on self-report in the
evaluation. While self-report may not be as accurate as
direct observation, the interviews were conducted as
soon as possible after the reviews to improve GPs’ recall
and reliability [33]. Furthermore, many implementation
outcomes may be best assessed using participants’
expressed attitudes and opinions, intentions or reported
behaviours [19, 20].
We used our sample to purposively explore implemen-
tation in diverse practice contexts rather than to be sta-
tistically representative. The GPs who volunteered for
this study are more likely to be early innovators or
adopters of any improvement intervention. However, the
characteristics of participating practices improve the
generalisability of our results, something that implemen-
tation studies are frequently criticised for [20, 32].
While the qualitative findings from the feasibility
study suggest that MY COMRADE has the potential
to impact on referrals to secondary care, inappropriate
prescribing and improve metrics of chronic disease
care, the full scope and magnitude of effect associated
with this approach has yet to be determined. Addition-
ally, while the feasibility study addressed key uncer-
tainties relating to the intervention’s acceptability, it
did not test all uncertainties which must be answered
prior to proceeding with a definitive trial of effective-
ness of MY COMRADE. A pilot randomised con-
trolled trial is now required to answer these
uncertainties which include: choosing the most appro-
priate means for recruitment and randomisation of
practices and patients; determining the time and staff
requirements at the level of participating practices and
the level of the research team; clarifying means of data
collection from practices and patients; answering
questions regarding the expected level of correlation
within practices and choosing the most appropriate
primary outcome for the definitive trial. Feasibility
studies may be followed by pilot studies [17]; in this
case, we feel such linear progression is warranted and
will ultimately enhance the rigour and efficiency of the
definitive trial.
Conclusions
The MY COMRADE implementation intervention is a
response to the call for interventions to support medica-
tion management in patients with multimorbidity. The
intervention utilises protected time and peer support to
facilitate structured medication review by GPs and gen-
erate an optimised medication management plan for a
complex multimorbid patient. In this feasibility study,
we found that MY COMRADE is acceptable to GPs, is
adaptable to individual general practices and consistently
leads to the generation of recommendations for medica-
tion optimisation. These findings suggest that MY
COMRADE has the potential to make a significant con-
tribution in improving clinical outcomes for patients
with multimorbidity and justify the conduct of a larger
scale trial of the intervention’s effectiveness.
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